Scrip
20 April 2009
Nancy Faigen
Procter & Gamble is testing a programme through which it will back up the efficacy of Actonel (risedronate sodium) and reimburse a US insurer for the cost of treating non-spinal, osteoporosis-related fractures in patients on the product.
This would entail reimbursements for fractures...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE osteoporotic fracture guidance unchanged despite legal challenge
- NICE to review guidance on Servier's Protelos after legal challenge
- Bisphosphonates may not increase risk of femoral fractures, study finds
- US doctors likely to keep denosumab as second- or third-line therapy for PMO
ANALYSIS
- Executive Briefing - Battle lines drawn over parallel trade
- Executive Briefing - Getting to grips with advanced therapies in the EU
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
